October 2, 2018
Venatorx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for Cefepime/VNRX-5133 at IDWeek 2018
Posters for Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be presented on Friday, October 5, 2018 in S Poster Hall from 12:30pm to 1:45pm PT.
September 25, 2018
Venatorx Pharmaceuticals and Everest Medicines II Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
Venatorx Pharmaceuticals entered into an exclusive license agreement with Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company with operations based in China, to support the development, registration and commercialization of cefepime/VNRX-5133 in Greater China, South Korea and Southeast Asia for complicated urinary tract infections (cUTI), infections due to carbapenem resistant pathogens, and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).
September 4, 2018
Antibiotic Class Emerges through Digestive Enzyme, find out more at 3rd Annual Superbugs and Superdrugs USA Conference
SMi Group is proud to announce the return of the Superbugs & Superdrugs USA conference to Iselin, NJ on the 12th and 13th November 2018.
August 9, 2018
Venatorx was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal. Founded in 2010, VenatoRx has grown from three founders to over 50 employees who are heavily comprised of entrepreneurial-minded scientists and operators who have had career success in big pharma and start-up environments.
May 31, 2018
Venatorx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks
Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, will be featured in the New Agents Discovery Summary Session: Early New Antimicrobial Agents; Emerging Tech Talks; and five poster presentations.
May 17, 2018
President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of Venatorx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.
April 19, 2018
Venatorx Pharmaceuticals Founders Christopher J. Burns, Ph.D., Luigi Xerri, Ph.D. and Daniel C. Pevear, Ph.D. named EY Entrepreneur Of The Year 2018 Finalists in the Greater Philadelphia Area
The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Drs. Burns, Xerri and Pevear were selected as finalists by a panel of independent judges. Award winners will be announced at a special gala event on June 14, 2018 at the Kimmel Center for the Performing Arts.
April 12, 2018
Fourteen poster presentations, including four oral sessions, will feature Venatorx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, Venatorx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.
March 19, 2018
Venatorx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting
President and CEO, Christopher J. Burns, Ph.D., will present the Company's lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium at the American Chemical Society (ACS) National Meeting on Wednesday, March 21, 2018 at 3:15pm CT. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”
January 4, 2018
Venatorx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
The funding will support discovery and preclinical development of a novel, first-in-class antibiotic for biodefense applications. The project derives from the company’s proprietary platform of non-beta-lactam penicillin binding protein inhibitors (PBPi).
January 3, 2018
Venatorx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program
The FDA granted Venatorx's lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, both the Qualified Infectious Disease Product (QIDP) and Fast Track designations. The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).